Back
Clear Blue Technologies International, Inc. 10K Form
Buy
63
CBLU.V
Clear Blue Technologies International, Inc.
Last Price:
$0.07
Seasonality Move:
17.75%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive CBLU.V News And Ratings
See the #1 stock for the next 7 days that we like better than CBLU.V
CBLU.V Financial Statistics
Sales & Book Value
| Annual Sales: | $2.8M |
|---|---|
| Cash Flow: | $-1.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.07 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.10560 |
|---|---|
| Net Income (TTM): | $-8.2M |
| Gross Margin: | $-740.4K |
| Return on Equity: | 0% |
| Return on Assets: | -118.6% |
Clear Blue Technologies International, Inc. Earnings Forecast
Key Clear Blue Technologies International, Inc. Financial Ratios
-
The Gross Profit Margin over the past 9 years for CBLU.V is -26.84%.
-
The Selling, General & Administrative Expenses for CBLU.V have been equal to 55.64% of Gross Profit Margin.
-
The Research & Development expenses have been 15.75% of Revenue.
-
The Net Earning history of CBLU.V is -399.75% of Total Revenues.
-
Per Share Earnings over the last 9 years have been positive in 5 years.
Clear Blue Technologies International, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | TSXV |
|---|---|
| Industry: | Independent Power & Renewable Electricity Producer |
| Sector: | Utilities |
| Current Symbol: | CBLU.V |
| Website: | clearbluetechnologies.com |
Debt
| Debt-to-Equity Ratio: | -1.17 |
|---|---|
| Current Ratio: | 1.22 |
| Quick Ratio: | 0.26 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CBLU.V Technical Analysis vs Fundamental Analysis
Buy
63
Clear Blue Technologies International, Inc. (CBLU.V)
is a Buy
Is Clear Blue Technologies International, Inc. a Buy or a Sell?
-
Clear Blue Technologies International, Inc. stock is rated a BuyThe current Clear Blue Technologies International, Inc. [CBLU.V] share price is $0.07. The Score for CBLU.V is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.